Baxter’s Long-Term Goals – Analyst Blog
Source: http://www.zacks.com/stock/news/24999/Baxter%27s+Long-Term+Goals+-+Analyst+BlogPosted on Friday, September 18th, 2009 | In Investing Lessons, Stocks to Watch
Baxter International Inc. (BAX) discussed its long-term financial objectives, growth opportunities and various research and development (R&D) programs at its recently concluded Investor Conference in Chicago.
The long-term (5-year) financial objectives are as follows:
- Increase sales roughly 7% to 8% per annum, excluding foreign exchange translation effect
- Grow earnings per share in the range of 11% to 13% per annum
- Generate annual cash flow of approximately $4 billion by 2014
Baxter also plans to expand its strong existing product portfolio by enhancing R&D investments at a compound annual rate of a minimum 8% to 10% from 7% at the end of fiscal 2008. The company will continue to hunt for business development opportunities through its disciplined acquisition strategy.
We are confident that Baxter will be able to deliver on its commitments. The company has achieved record sales, earnings and strong cash flows over the past few years. Baxter has initiated 14 phase III clinical trials in the last year and is conducting several early-stage trials that have the potential to increase efficiency in the treatment of several chronic diseases like cardiovascular, kidney failure, Alzheimer’s, etc.
Baxter is a leading global medical products and services company that develops, manufactures and markets products to save the lives of millions of people affected by hemophilia, kidney disease, infectious diseases, etc. Baxter’s life-sustaining product portfolio is a hedge against the current economic turmoil. The company’s main competitors include Becton, Dickinson and Co. (BDX) and Johnson & Johnson (JNJ).
Read the full analyst report on “BAX”
Read the full analyst report on “BDX”
Read the full analyst report on “JNJ”
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- Steel Dynamics Raises Debt - Analyst Blog - March 19th, 2010
- DuPont Focus on Plant Genetics - Analyst Blog - March 19th, 2010
- Ford Receives Grants - Analyst Blog - March 19th, 2010
- HD to roll out Spring Black Friday - Analyst Blog - March 19th, 2010
- PPL Awards $70M Contract, Builds Jobs - Analyst Blog - March 19th, 2010
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.